THS et risque de cancer du sein - Résultats de la cohorte E3N

Agnès Fournier; Franco Berrino; Elio Riboli; Valérie Avenel; Françoise Clavel-Chapelon

THS et risque de cancer du sein - Résultats de la cohorte E3N

Translated title of the contribution: HRT and breast cancer risk - Results of the E3N-EPIC cohort

Agnès Fournier, Franco Berrino, Elio Riboli, Valérie Avenel, Françoise Clavel-Chapelon

Fondazione IRCCS Istituto Nazionale dei Tumori

Research output: Contribution to journal › Article › peer-review

Abstract

Most epidemiological studies have shown an increase in breast cancer risk related to hormone replacement therapy (HRT) use. We assessed the risk of breast cancer associated with HRT use in 54,548 postmenopausal women who had never taken any HRT one year before entering the E3N-EPIC cohort study (mean age at inclusion: 52.8 years). 948 primary invasive breast cancers were diagnosed during follow-up (mean duration: 5.8 years). Data were analysed using multivariate Cox proportional hazards models. In this cohort where the mean duration of HRT use was 2.8 years, an increased risk in HRT users compared with non-users was found (relative risk (RR) 1.2 [95% confidence interval 1.1-1.4]). The RR was 1.1 [0.8-1.6] for estrogens used alone and 1.3 [1.1-1.5] when used in combination with oral progestogens. The risk was significantly greater (p

Translated title of the contribution	HRT and breast cancer risk - Results of the E3N-EPIC cohort
Original language	French
Pages (from-to)	186-193
Number of pages	8
Journal	Reproduction Humaine et Hormones
Volume	18
Issue number	5
Publication status	Published - Jun 2005

Keywords

Breast cancer
Cohort study
Hormone Replacement Therapy
Menopause
Risk factor

ASJC Scopus subject areas

Obstetrics and Gynaecology

Cite this

@article{ce4f751ce3d5483ba31b8d4324901450,

title = "THS et risque de cancer du sein - R{\'e}sultats de la cohorte E3N",

abstract = "Most epidemiological studies have shown an increase in breast cancer risk related to hormone replacement therapy (HRT) use. We assessed the risk of breast cancer associated with HRT use in 54,548 postmenopausal women who had never taken any HRT one year before entering the E3N-EPIC cohort study (mean age at inclusion: 52.8 years). 948 primary invasive breast cancers were diagnosed during follow-up (mean duration: 5.8 years). Data were analysed using multivariate Cox proportional hazards models. In this cohort where the mean duration of HRT use was 2.8 years, an increased risk in HRT users compared with non-users was found (relative risk (RR) 1.2 [95% confidence interval 1.1-1.4]). The RR was 1.1 [0.8-1.6] for estrogens used alone and 1.3 [1.1-1.5] when used in combination with oral progestogens. The risk was significantly greater (p ",

keywords = "Breast cancer, Cohort study, Hormone Replacement Therapy, Menopause, Risk factor",

author = "Agn{\`e}s Fournier and Franco Berrino and Elio Riboli and Val{\'e}rie Avenel and Fran{\c c}oise Clavel-Chapelon",

year = "2005",

month = jun,

language = "Francese",

volume = "18",

pages = "186--193",

journal = "Reproduction Humaine et Hormones",

issn = "0994-3919",

publisher = "Editions ESKA",

number = "5",

}

TY - JOUR

T1 - THS et risque de cancer du sein - Résultats de la cohorte E3N

AU - Fournier, Agnès

AU - Berrino, Franco

AU - Riboli, Elio

AU - Avenel, Valérie

AU - Clavel-Chapelon, Françoise

PY - 2005/6

Y1 - 2005/6

N2 - Most epidemiological studies have shown an increase in breast cancer risk related to hormone replacement therapy (HRT) use. We assessed the risk of breast cancer associated with HRT use in 54,548 postmenopausal women who had never taken any HRT one year before entering the E3N-EPIC cohort study (mean age at inclusion: 52.8 years). 948 primary invasive breast cancers were diagnosed during follow-up (mean duration: 5.8 years). Data were analysed using multivariate Cox proportional hazards models. In this cohort where the mean duration of HRT use was 2.8 years, an increased risk in HRT users compared with non-users was found (relative risk (RR) 1.2 [95% confidence interval 1.1-1.4]). The RR was 1.1 [0.8-1.6] for estrogens used alone and 1.3 [1.1-1.5] when used in combination with oral progestogens. The risk was significantly greater (p

AB - Most epidemiological studies have shown an increase in breast cancer risk related to hormone replacement therapy (HRT) use. We assessed the risk of breast cancer associated with HRT use in 54,548 postmenopausal women who had never taken any HRT one year before entering the E3N-EPIC cohort study (mean age at inclusion: 52.8 years). 948 primary invasive breast cancers were diagnosed during follow-up (mean duration: 5.8 years). Data were analysed using multivariate Cox proportional hazards models. In this cohort where the mean duration of HRT use was 2.8 years, an increased risk in HRT users compared with non-users was found (relative risk (RR) 1.2 [95% confidence interval 1.1-1.4]). The RR was 1.1 [0.8-1.6] for estrogens used alone and 1.3 [1.1-1.5] when used in combination with oral progestogens. The risk was significantly greater (p

KW - Breast cancer

KW - Cohort study

KW - Hormone Replacement Therapy

KW - Menopause

KW - Risk factor

UR - http://www.scopus.com/inward/record.url?scp=23644458144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23644458144&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:23644458144

VL - 18

SP - 186

EP - 193

JO - Reproduction Humaine et Hormones

JF - Reproduction Humaine et Hormones

SN - 0994-3919

IS - 5

ER -

THS et risque de cancer du sein - Résultats de la cohorte E3N

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this